GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
One good thing, Now thrail trial has found citical mass of cohorts to reach 8 week, we could be in for a period of news .. in theory 12 week monitoring results of the first 14 will follow through within a couple of weeks - we know that this is when the second scan is conducted
Hi Chester
Fair point - you are right - there are load of AIM dogs that get ramped and TBH I prefer to buy before you have a 1000,s post a day .. however as I’ve only been here a short while I don’t think I have any reason to judge a ten year holder !! - I suppose my only key doubt about SCLP ties into your post above . How can a company do small come up with something that isn’t easily within the grasp of multi billion companies and if it works and is advancing well in medical trials the wording of an rnS is irrelevant as PI won’t bring out the value .. but I do need to catch up On history .. with scancell there’s a lot of it .. I remember this used to be a Tom Winnifrith fav ?
It seems like the next year could be a pivotal moment though
Not sure why the focus is Ona single word - doesn’t change anything and at the it’s not the point of RNS to ramp the price .. there is plently more that could be said , the results are for 8weeks - we have so patients that are now approching 5 month+ of treatment and we know at 12 weeks one person had 55% reduction - but this isn’t about ramping for traders , we will get another timely update as the trail get thicker and level .. the RNS was good and reflected the first 8 weeks for 14 cohorts - adding Very in the title doesn’t change a thing IMO Cheers
Great Thread .. Thanks for taking the time.. some very knowegable and commited Shareholders on here.. makes refreshing a change from nutters all over LSE and ADVFN ..
I would have thought Tumors vanishing is way past any endpoint expected.. compared to pallative care on the table for many people on the trial and in this terrible postion, stable alone is better than anything currently available on by some margin ..
Many Thanks Bermuda /All - Thats really clear
Hi Bermuda
What you are saying makes perfect sense - I was sure i read in an RNS/post somewhere , but checking back I must have misunderstood.
CH1 looks to have been 3-6 patients ..I am curious how CH1 tie into the RNS Efficacy statement. I think the below is all we have to go on .. Its certainly not easy to work out - total vaccines to date 55? Cheers
Cohort 1 of the study confirmed the safety profile of a low dose of two citrullinated vimentin peptides. The objective for Cohort 2 of the trial was to assess the safety of the two citrullinated vimentin peptides plus an enolase peptide at a higher dose. Based on the safety data from Cohort 2, the ModiFY trial was expanded at this recommended Phase 2 dose for Modi-1 monotherapy in all four tumour types. In parallel, Cohort 3 is recruiting patients to receive Modi-1 plus a CPI. To date, 23 patients have been vaccinated, 18 with HGSOC, two with TNBC, two with SCCHN and one with RCC, with 55 doses being administered in total.
One thing I struggled to get my head around is the dosing and check points .. from reseaching the information posted by the brave volenterrs in this trial is that th information given in the RNS demstrates the significant lag in reporting untill majority of the cohort reached a certain stage. these are my assmuptions on how the trial is progressing ?
Cohort 2 each patient is given a vaccine every 4 weeks /month
Scans appear to have been done 8/12/24 weeks
Cohort 2 first patients have already had thier 24 week scan mid feb.
RNS only reports 8 weeks for 14 patients, which suggest one patient per week, but alot more data to come through as upto about 23 week gap from first to last of Cohort 2
possible 12 week results for first 14 could flow through soon.
Notsure where CH1 fit in at all .. It appear they migrate to CH2 which would be good news,
I agree - it think there is a huge amount of information to be digested by the trial team - Tumor size is great but is only a crude indication … the effectiveness and shape of the trial will come from a microscope and all those specific bio markers that build a complete picture. The Tilly story is amazing, it’s shows the potential for a new standard of care, more data will come .. looking forward to it
Hi All
I do find the update a little confusing.. Its lacks spcrfics around the cohorts 1/2 and nothing between the different cancers..but for me the words from Dr David Pinato are very important - Advanced agressive Cancers do not sabilise on thier own.. Looking forwards to the next update ..
From the Presentation using PEA resource = Current NPV US$247m @Spot price = US$389m @Long term concensus = US$314m
March 23 Presentation
One interesting take is that, they appear almost ready to issue the resource upgrade (end of feb early march) so that will give some numbers to crunch on the put option.. looks like that may drop any day
https://s21.q4cdn.com/765868678/files/doc_presentations/2023/03/2023-Ascendant-Corporate-Presentation-March.pdf
Looking forward to an update on the biopsy , could be big news
Durrant. Referring to unpublished data from an ongoing trial, she mentions that one patient has demonstrated a 36% reduction
in tumour size after just two immunisations (of a total of five).
Biopsies from this patient are
due to be analysed to confirm the presence and activity of immune cells.
Durrant says, “I can’t really believe that result yet; we need to get more.” Around 140 patients will take
part in the phase 1/2 trial, due to complete in 2026.
Should have put that in the RNS - we would be at 40p :0) ..When you look at the patient critera for the trial it puts into context how important stable and partial mean - some very ill people on this trial .. Having recently watched my mum suffer and die from bowel cancer, i feel that people at this stage of treatment really have not much hope left..only hope that it bring an extention of life to the cohorts, all very brave people. I dont think the significance on the first piece of data has been taken in
Agree - The thing is even best brains in the World havent fully worked out DTH Relationship yet..The below is link to a clincial trial into this very subject . Intro and final discussion are worth a but read..but TBH a Broker cant say much more other than cut n paste the RNS from the professor.. See BelowFYI
https://aacrjournals.org/clincancerres/article/6/4/1347/288151/Delayed-Type-Hypersensitivity-Response-Is-a
INTRODUCTION
The proposed end point of many initial studies of cancer vaccines is the ability to generate an immune response against a cancer antigen or the correlation of an antitumor response to some measure of immunity. At present, there is no standard methodology for measuring cell-mediated immune responses elicited by cancer vaccines. Recent advances in molecular tumor immunology have resulted in the identification of several specific tumor antigens defined by virtue of their immunogenicity in cancer patients (1, 2). Immunizing against a specific tumor antigen allows the comparison of methods to measure tumor-specific immunity and a statistical assessment of the validity of various means of cancer vaccine immunological monitoring. DTH3 responses are the most common, most widely available measurements, and one of the few measurements used to determine effective tumor immunization. However,little is known about the ability of DTH to actually reflect the development of systemic tumor-specific immunity in cancer patients after vaccination.
Morning re DHT
My thoughts - I’d you check clinical trail one the primary end point is the measurement of Cellular immune response.
https://clinicaltrials.gov/ct2/show/NCT05329532
There are four types of hypersensitivity
four types of hypersensitivity are:
Type I: reaction mediated by IgE antibodies.
Type II: cytotoxic reaction mediated by IgG or IgM antibodies.
Type III: reaction mediated by immune complexes.
Type IV: delayed reaction mediated by cellular response.
So FWIW from my layman view - DHT is a very good sign that at least one of the primary end points is being met ..Cheers
ading the RNS again it would seem that the results that we were presented were from the dose finding Arm and not the expansion phase started at the end of October? reading the text below the reluts are ver early.
As no dose limiting toxicities were observed in the monotherapy dose escalation cohorts, patients continue to be enrolled into both the ongoing monotherapy expansion cohorts and the CPI combination dose escalation cohorts during H1 2023.
Thanks all
Ive been trying to get my head round it …I didnt know about the first being 3 patients – Expanded end of October -Assume this would be both C1 and C2 in the expansion phase? or C2 only - Then in Jan 14 prople dosed in expansion.. and then at last update Feb – 23 given (in total) … but I whats not clear is how often the dosing is repeated and where the checkpoints are 8 12 etc .. I cut n paste the below into word to work it out .. anyone aware of any other documnetation .. I have read the AGM .. But doesnt go to a lower level
13th June
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the enrolment and treatment of the first patient in its multicentre Modi-1 clinical trial (ModiFY) at Imperial College London, Hammersmith Hospital.
16th Aug
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that the first patient in Cohort 2 of the multicentre Phase 1 Modi-1 clinical trial (ModiFY) has been enroled and dosed. The dosing follows approval of the dose escalation by the Safety Review Board.
31st October
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that the first patient in the expansion phase of the monotherapy arms in the multicentre Phase 1 Modi-1 clinical trial (ModiFY) has been enrolled and dosed. In addition, Cohort 3 of ModiFY is now open for recruitment in combination with a checkpoint inhibitor (CPI). Expansion into the monotherapy arms and the start of combination dosing follows review of the safety data from the Cohort 2 patients by the Safety Review Board
27th Jan
Fourteen patients enrolled and dosed in the expansion phase of the monotherapy arms in the multicentre Phase 1/2 Modi-1 clinical trial (ModiFY). First patient dosed in Cohort 3 of ModiFY in combination with a checkpoint inhibitor (CPI). There have been no safety issues to date.
Feb
To date, 23 patients have been vaccinated with Modi-1 and all have had skin reactions at the injection sites consistent with a delayed-type hypersensitivity (DTH) reaction indicative of a T cell response. So far, initial clinical responses have been assessed in 14 patients reaching the first imaging evaluation timepoint at week 8
Morning
I have been lurking here for a while, some useful posts on here - After following for a while bought in day after RNS..
Silly question - of the 14 paitents tested -How many were Corhort 1 / Cohort 2 ? I've looked through the RNS's and find them a bit confusing as first paitents were given the vaxine some time ago .. TIA Cheers
This has to be RNS'd either way
On 15 February 2023, Eliot & Luther (“E&L”) informed the Audioboom Board and its financial
advisors that it has entered into an initial Consortium Agreement in respect of ordinary
Audioboom shares representing more than 10% of the current outstanding shares
I think around thia level there is no real benefit in Xak theory - However something is definately up .. either an scheme to decieve..or the first steps in aquiring BOOM on the cheap .. wouldnt be suprised if the future members of the consetuim aleary have thier 29.9 percent